IS CANNABIS SATIVA, THE MIND ALTERING NIGHTMARE PLANT OF THE WORLD?

Raghavendra M. V Rao, Tiara Calvo, Frank Navarrete, Mahendra K. Verma, Abrar A Khan, R. K. Kudari, Kumar Ponnusamy, Siva Anoop Yella, Badam Aruna Kumari, Dilip Mathai

Abstract


Cannabis Sativa is the hatred weed. Marijuana, is popularly known as pot, weed, ganja, Mary jane nicknames. Marijuana, far-reaching well liked mind-boggling medicaments across the globe. Cannabis Smolder assassinated, but consuming marijuana could stretch out the growth of cancer. This is used as hallucinogenic materials by man from times immemorial. Due to its known ability to induce euphoria and relaxation, cannabis (marijuana) commonly-used substances worldwide for decades.

 

Transitory use of the drug debilitates reasoning and planning. In prolonged studies, teens who smoke marijuana have lower IQs afterwards. When puff on, marijuana releases cannabinoids, which produce neurotransmitters in brain. These cannabinoids give medicinal value to Marizona.The cannabinoids acknowledge dissimilar domains of the brain exert influence on memory, pleasure and muscle movement. Marijuana has delta-9-tetrahydrocannabinol (THC) which binds to CB1 brain cannabis receptor.

Keywords


THC acts by preventing the delivery of L-glutamate, GABA, noradrenaline, dopamine, 5-HT and acetylcholine.

Full Text:

PDF

References


Jacob W. Baltz, and Lam Anh T. Le, Serotonin Syndrome versus Cannabis Toxicity in the Emergency Department,ClinPract Cases Emerg Med. 2020 May; 4(2): 171–173.

Volkow ND, Baler R. Emergency department visits from edible versus inhalable cannabis. Ann Intern Med. 2019;170(8):569–70

Rickner SS, Cao D, Kleinschmidt K, et al. A little “dab” will do ya’ in: a case report of neuro-and cardiotoxicity following use of cannabis concentrates. ClinToxicol (Phila) 2017;55(9):1011–3

Boyer EW, Shannon M. The serotonin syndrome. N Engl J Med. 2005;352(11):1112–20

Wade L. Hardcore Pot Smoking Could Damage the Brain's Pleasure Center. Science. 2014

NIH: National Institute on Drug Abuse. Marijuana, 2007. www.drugabuse.gov (accessed June 15, 2016

Cheer JF, Wassum KM, Sombers LA, Heien ML, Ariansen JL, Aragona BJ, Phillips PE, Wightman RM 2007. Phasic dopamine release evoked by abused substances requires cannabinoid receptor activation. J Neurosci 27: 791–795

Aragona BJ, Cleaveland NA, Stuber GD, Day JJ, Carelli RM, Wightman RM 2008. Preferential enhancement of dopamine transmission within the nucleus accumbens shell by cocaine is attributable to a direct increase in phasic dopamine release events. J Neurosci 28: 8821–8831

Vries T, Schoffelmeer A 2005. Cannabinoid CB1 receptors control conditioned drug seeking. Trends PharmacolSci 26: 420–426

Solinas M, Goldberg SR, Piomelli D 2008. The endocannabinoid system in brain reward processes. Br J Pharmacol 154: 369–383

Breivogel CS, Griffin G, Di Marzo V, Martin BR. Evidence for a new G protein-coupled cannabinoid receptor in mouse brain. MolPharmacol. 2001;60:155–163

Onaivi ES. Neuropsych Biological evidence for the functional presence and expression of cannabinoid CB2 receptors in the brain. Neuropsychobiology. 2006;54:231–246

Boggs D. L., Nguyen J. D., Morgenson D., Taffe M. A., Ranganathan M. Clinical and preclinical evidence for functional interactions of cannabidiol and Δ9-tetrahydrocannabinol. Neuropsychopharmacology 2018; 43: 142–54.

Volkow N. D., Swanson J. M., Evins A. E., DeLisi L. E., Meier M. H., Gonzalez R. et al. Effects of cannabis use on Published 2020.

.15. National Academies of Sciences, Engineering, and Medicine. In: The Health Effects of Cannabis and Cannabinoids: The Current State of Evidence and Recommendations for Research. Washington, DC: National Academies Press; 2017.

Tahir, M.N., Shahbazi, F., Rondeau-Gagné, S. et al. The biosynthesis of the cannabinoids. J Cannabis Res 3, 7 (2021).

Luo, X., Reiter, M.A., d’Espaux, L. et al. Complete biosynthesis of cannabinoids and their unnatural analogues in yeast. Nature567, 123–126 (2019)

Thies G. et al (2020) Phytocannabinoids: Origins and Biosynthesis. Trends in plant Science Vol 25, Issue 10, p947-1054.

- An D, Peigneur S, Hendrickx LA, Tytgat J. Targeting Cannabinoid Receptors: Current Status and Prospects of Natural Products. Int J Mol Sci. 2020;21(14):5064. Published 2020 Jul 17. doi:10.3390/ijms21145064

Mackie K. Cannabinoid receptors: where they are and what they do. J Neuroendocrinol. 2008 May;20 Suppl 1:10-4. doi: 10.1111/j.1365-2826.2008.01671.x. PMID: 18426493.

Jahan P. Marcu, et al (2016) Molecular Pharmacology of CB1 and CB2 Cannabinoid Receptors. Neuropathology of Drug Addictions and Substance Misuse, AcademicPress,2016, Pages 713-721,

Cáceres Guido P, Riva N, Calle G, Dell'Orso M, Gatto M, Sberna N, Schaiquevich P. Medicinal cannabis in Latin America: History, current state of regulation, and the role of the pharmacist in a new clinical experience with cannabidiol oil. J Am Pharm Assoc (2003). 2020 Jan-Feb;60(1):212-215.

Murray, R. M.; Morrison, P. D.; Henquet, C.; Di Forti, M. Nat. Rev. Neurosci. 2007, 8 (11), 885−895.

United Nations Office on Drugs and Crime (UNODC). World Drug Report, 2014.

Hall, W.; Degenhardt, L. Lancet 2009, 374 (9698), 1383−1391.

Moir, D.; Rickert, W. S.; Levasseur, G.; Larose, Y.; Maertens, R.; White, P.; Desjardins, S. Chem. Res. Toxicol. 2008, 21 (2), 494−502.

Volkow, N. D.; Baler, R. D.; Compton, W. M.; Weiss, S. R. N. Engl. J. Med. 2014, 370 (23), 2219−2227.

Kemp, P. M.; Abukhalaf, I. K.; Manno, J. E.; Manno, B. R.; Alford, D. D.; Abusada, G. A. J. Anal. Toxicol. 1995, 19 (5), 285−291.

Grauwiler, S. B.; Scholer, A.; Drewe, J. J. Chromatogr. B: Anal. Technol. Biomed. Life Sci. 2007, 850 (1), 515−522.

Fernández, M. d. M. R.; Wille, S. M.; Samyn, N.; Wood, M.; López-Rivadulla, M.; De Boeck, G. J. Chromatogr. B: Anal. Technol. Biomed. Life Sci. 2009, 877 (22), 2153−2157.

Substance Abuse and Mental Health Administration. Mandatory guidelines for federal workplace drug testing programs 2000. www.health.org/workplace/manguidelines/draft3.htm

N. Samyn, A. Verstraete, C. van Haeren, and P. Kintz. Analysis of drugs of abuse in saliva. Forensic ScL Rev. 11:1-19 (1999).

L.K. Thompson and E.J. Cone. Determination of delta-9-tetrahydrocannabinol in human blood and saliva by high-performance liquid chromatography with amperometric detection. J. Chromatogr. 421: 91-97 (1987).

C. Maseda, K. Hama, Y. Fukui, K. Matsubara, S. Takahashi, and A. Akane. Detection of delta-9-THC in saliva by capillary GC/ECD after marihuana smoking. Forensic Sci. Int. 32:259-266 (1986).

W.W. Just, N. Filipovic, and G. Werner. Detection of delta-9-tetrahydrocannabinol in saliva of men by means of thin-layer chromatography and mass spectrometry. J. Chromatogr. 96' 189-194

(1974).

R.L. Hawks. Developments in cannabinoid analyses of body fluids: implications for forensic applications. In The Cannabinoids:Chemical, Pharmacologic, and Therapeutic Aspects, S. Agurell, W. Dewey, and R. Willette, Eds. Academic Press, Rockville, MD, 1983, pp 1-12.

W.W. Just, G. Werner, G. Erdmann, and M. Wiechmann. Detection and identification of delta-8- and delta-9-tetrahydrocannabinol in saliva of man and autoradiographic investigation of their distribution in different organs of the monkey. Strahlentherapie74' 90-97, (1975).

W. Schramm, R.H. Smith, RA. Craig, and D.A. Kidwell. Drugs of abuse in saliva: a review. ]. Anal. Toxicol. 16:1-9 (1992).

M.A. Huestis and E.J. Cone. Alternative testing matrices. In Drug Abuse Handbook, S. Karch, Ed. CRC Press, Boca Raton, FL, 1998, pp 799-857.

M.A. Huestis, J.E. Henningfield, and E.J. Cone. Blood cannabinoids. I. Absorption of THC and formation of 11-OH-THC and THCCOOH during and after smoking marijuana. J. Anal Toxicol. 16" 276-282, (1992).

D.J. Harvey and W.D.M. Paton. Metabolism of the cannabinoids. Rev. Biochem. ToxicoL6:221-264 (1986).

M.A. Huestis, J.M. Mitchell, and E.J. Cone. Detection times of marijuana metabolites in urine by immunoassay and GC-MS. J. Anal. Toxicol. 19:443-449 (1995).

G.M. Ellis, M.A. Mann, B.A. Judson, N.T. Schramm, and A. Tashchian. Excretion patterns of cannabinoid metabolites after last use in a group of chronic users. Clin. Pharmacol. Ther. 38: 572-578 (1985).

R.L. Hawks. Developments in cannabinoid analyses of body fluids: implications for forensic applications. In The Cannabinoids: Chemical, Pharmacologic, and Therapeutic Aspects, S. Agurell, W. Dewey, and R. Willette, Eds. Academic Press, Rockville, MD, 1983, pp 1-12.

Nguyen BM, Kim D, Bricker S, et al. Effect of Marijuana Use on Outcomes in Traumatic Brain Injury. The American Surgeon. 2014;80(10):979-983.

SharvenTaghavi, Saul Ramirez, Juan Duchesne, Danielle Tatum, Preinjury Use of Marijuana and Outcomes in Trauma Patients,Journal of Surgical Research,Volume 257,2021,Pages 42-49,

Mori MA, Meyer E, Soares LM, Milani H, Guimarães FS, de Oliveira RMW. Cannabidiol reduces neuroinflammation and promotes neuroplasticity and functional recovery after brain ischemia. ProgNeuropsychopharmacolBiol Psychiatry. 2017 Apr 3;75:94-105

Navarrete C, García-Martín A, Rolland A, DeMesa J, Muñoz E. Cannabidiol and Other Cannabinoids in Demyelinating Diseases. International Journal of Molecular Sciences. 2021; 22(6):2992

Uddin MS, Mamun AA, Sumsuzzman DM, et al. Emerging Promise of Cannabinoids for the Management of Pain and Associated Neuropathological Alterations in Alzheimer's Disease. Front Pharmacol. 2020;11:1097. Published 2020 Jul 22.

Amen, Daniel G. et al. ‘Discriminative Properties of Hippocampal Hypoperfusion in Marijuana Users Compared to Healthy Controls: Implications for Marijuana Administration in Alzheimer’s Dementia’. 1 Jan. 2017 : 261 – 273.

Kim SH, Yang JW, Kim KH, Kim JU, Yook TH. A Review on Studies of Marijuana for Alzheimer's Disease - Focusing on CBD, THC. J Pharmacopuncture. 2019;22(4):225-230.

Halladay JE, Munn C, Boyle M, Jack SM, Georgiades K. Temporal Changes in the Cross-Sectional Associations between Cannabis Use, Suicidal Ideation, and Depression in a Nationally Representative Sample of Canadian Adults in 2012 Compared to 2002. Can J Psychiatry. 2020;65(2):115-123.

Haleem R, Wright R. A Scoping Review on Clinical Trials of Pain Reduction With Cannabis Administration in Adults. J Clin Med Res. 2020;12(6):344-351

De Vries M, van Rijckevorsel DCM, Vissers KCP, Wilder-Smith OHG, van Goor H; Pain and Nociception Neuroscience Research Group. Tetrahydrocannabinol Does Not Reduce Pain in Patients With Chronic Abdominal Pain in a Phase 2 Placebo-controlled Study. ClinGastroenterolHepatol. 2017 Jul;15(7):1079-1086.e4. doi: 10.1016/j.cgh.2016.09.147. Epub 2016 Oct 5

Amaniti A, Sardeli C, Fyntanidou V, Papakonstantinou P, Dalakakis I, Mylonas A, Sapalidis K, Kosmidis C, Katsaounis A, Giannakidis D, Koulouris C, Aidoni Z, Michalopoulos N, Zarogoulidis P, Kesisoglou I, Ioannidis A, Vagionas A, Romanidis K, Oikonomou P, Grosomanidis V. Pharmacologic and Non-Pharmacologic Interventions for HIV-Neuropathy Pain. A Systematic Review and a Meta-Analysis. Medicina (Kaunas). 2019 Nov 28;55(12):762. doi: 10.3390/medicina55120762.

Mücke M, Phillips T, Radbruch L, Petzke F, Häuser W. Cannabis-based medicines for chronic neuropathic pain in adults. Cochrane Database Syst Rev. 2018;3(3):CD012182. Published 2018 Mar 7

Boland EG, Bennett MI, Allgar V, et alCannabinoids for adult cancer-related pain: systematic review and meta-analysisBMJ Supportive & Palliative Care 2020;10:14-24.

Black N, Stockings E, Campbell G, et al. Cannabinoids for the treatment of mental disorders and symptoms of mental disorders: a systematic review and meta-analysis [published correction appears in Lancet Psychiatry. 2020 Jan;7(1):e3]. Lancet Psychiatry. 2019;6(12):995-1010.

FDA regulation of Cannabis and Cannabis derived products. FDA.org website: Updated 1/22/21. Accessed 4/26/21

Orsolini L, Chiappini S, Volpe U, et al. Use of Medicinal Cannabis and Synthetic Cannabinoids in Post-Traumatic Stress Disorder (PTSD): A Systematic Review. Medicina (Kaunas). 2019;55(9):525. Published 2019 Aug 23

Botsford SL, Yang S, George TP. Cannabis and Cannabinoids in Mood and Anxiety Disorders: Impact on Illness Onset and Course, and Assessment of Therapeutic Potential. Am J Addict. 2020;29(1):9-26.

García-Gutiérrez MS, Navarrete F, Gasparyan A, Austrich-Olivares A, Sala F, Manzanares J. Cannabidiol: A Potential New Alternative for the Treatment of Anxiety, Depression, and Psychotic Disorders. Biomolecules. 2020;10(11):1575. Published 2020 Nov 19.

FDA regulation of Cannabis and Cannabis derived products. FDA.org website: Updated 1/22/21. Accessed 4/26/21.

European Monitoring Centre for Drugs and Drug Addiction publication on Medical Use of cannabis and cannabinoids of 2018 (EMCDDA website) Accessed 4/26/21.

Poyatos L, Pérez-Acevedo AP, Papaseit E, et al. Oral Administration of Cannabis and Δ-9-tetrahydrocannabinol (THC) Preparations: A Systematic Review. Medicina (Kaunas). 2020;56(6):309.

Levinsohn EA, Hill KP. Clinical uses of cannabis and cannabinoids in the United States. J Neurol Sci. 2020 Apr 15;411:116717. doi: 10.1016/j.jns.2020.116717. Epub 2020 Jan 30.


Refbacks

  • There are currently no refbacks.




Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.

Copyright © 2021 INTERNATIONAL EDUCATION AND RESEARCH JOURNAL